Shenzhen Chipscreen Biosciences Co., Ltd.

Nov 01, 2024

The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved

Oct 17, 2024

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted

Jul 19, 2024

Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration

Apr 30, 2024

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

Mar 18, 2024

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

Jan 10, 2021

Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA.

Jan 05, 2021

Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"

Dec 16, 2020

Chipscreen and HISUN reach a strategic cooperation

Mar 24, 2020

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted